AstraZeneca PLC Q3 2026 Earnings Recap

AstraZeneca shares rose 6.2% after the company reported 7% revenue growth and 14% core EPS growth for the first nine months, alongside continued pipeline progress. Growth excluding Farxiga and Brilinta was 12%, though the transcript also flags ongoing headwinds from those products’ loss of exclusivity and volume-based procurement in China.

Key Takeaways

• First-nine-month total revenue grew 7% and core EPS increased 14%; revenue growth was 12% excluding Farxiga and Brilinta.
• Oncology, rare disease and respiratory & immunology delivered double-digit growth, more than offsetting expected headwinds from Farxiga and Brilinta losses of exclusivity and CVRM.
• China growth remained affected by volume-based procurement; excluding that impact, the company said China grew 13%.
• AstraZeneca reported positive results from 12 Phase III programs since its full-year results and first approvals for four new medicines, bringing approved new molecular entities to 14.
• Management cited more than $10 billion in non-risk-adjusted peak-year sales potential from recent positive Phase III readouts, while noting that potential depends in part on future labels.